Trial Profile
Phase I Study of MK-3475 in Combination With BCG for Patients With High Risk Superficial Bladder Cancer
Status:
Active, no longer recruiting
Phase of Trial:
Phase I
Latest Information Update: 05 May 2023
Price :
$35
*
At a glance
- Drugs Bladder cancer vaccine (Primary) ; Pembrolizumab (Primary)
- Indications Bladder cancer
- Focus Adverse reactions
- Acronyms MARC
- 07 Jun 2022 Results assessing international prostate symptom score for intravesical bacillus Calmette-Guerin in patients high-grade non-muscle-invasive bladder cancer presented at the 58th Annual Meeting of the American Society of Clinical Oncology
- 16 May 2022 Results of two year efficacy follow up of phase 1 trial presented at the 117th Annual Meeting of the American Urological Association
- 12 May 2020 Status changed from recruiting to active, no longer recruiting.